GSK has announced plans to acquire efimosfermin, a Phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD).  The acquisition significantly expands GSK’s hepatology pipeline aimed at addressing steatotic and viral drivers of liver disease, offering multiple development options and potential first launch in 2029.  Under the agreement with […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!